

DÉB/AJC/jcc
July 27, 2000

-1-

Date: 7/27/00 Express Mail Label No. EL 551543910 US

Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup and Geertruida Veldman

Attorney's Docket No.: 1290.1019-013

SEE EXAM'S AND 4/15/05 ✓

METHODS OF TRANSPLANTING CELLS BY CONTACTING
DONOR CELLS WITH B7-1- AND B7-2- SPECIFIC
HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2 AND IMMUNOGLO
METHODS OF TREATMENT THEREWITH

RELATED APPLICATION(S)

This application is a divisional of U.S. Application No. 09/249,011 filed

- 5 February 12, 1999, the entire teachings of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

- Antigen specific T-cell activation and the initiation of an immune response depend initially on the interaction of the T-cell receptor (TCR) complex with the peptide/major histocompatibility complex (MHC) present on antigen presenting cells (APC). B7 molecules, B7-1 and B7-2, are molecules which are present on APCs. A second "costimulatory" signal, provided by the interaction of B7-1 and B7-2 on the APC with their ligands CD28 and CTLA4 on T-cells, is required to complete T-cell activation and the subsequent regulation of an immune response. A need exists to regulate the B7-1 and B7-2 pathway, referred to as the B7:cD28/CTLA4 pathway. A further need exists to develop treatments for diseases that are affected by this pathway.